MX2017013113A - Anticuerpos anti-pacap y sus usos. - Google Patents

Anticuerpos anti-pacap y sus usos.

Info

Publication number
MX2017013113A
MX2017013113A MX2017013113A MX2017013113A MX2017013113A MX 2017013113 A MX2017013113 A MX 2017013113A MX 2017013113 A MX2017013113 A MX 2017013113A MX 2017013113 A MX2017013113 A MX 2017013113A MX 2017013113 A MX2017013113 A MX 2017013113A
Authority
MX
Mexico
Prior art keywords
pacap
antibodies
binding fragments
antigen binding
vasodilation
Prior art date
Application number
MX2017013113A
Other languages
English (en)
Inventor
Latham John
H Dutzar Benjamin
J Billgren Jens
Loomis Maria-Cristina
Wayne Ojala Ethan
Fan Pei
S Allison Daniel
Lee HENDRIX Katherine
T L Smith Jeffrey
Karasek Charlie
Mulligan Jenny
Scalley-Kim Michelle
Stewart Erica
Lisbeth RUBIN Vanessa
Garcia-Martinez Leon
Original Assignee
Alder Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alder Biopharmaceuticals Inc filed Critical Alder Biopharmaceuticals Inc
Publication of MX2017013113A publication Critical patent/MX2017013113A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5757—Vasoactive intestinal peptide [VIP] or related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)

Abstract

La presente invención está dirigida a anticuerpos antagonistas y fragmentos de unión al antí­geno de estos que tienen especificidad de unión para PACAP. Estos anticuerpos inhiben, bloquean o neutralizan al menos un efecto biológico asociado con PACAP, por ejemplo, vasodilatación. En modalidades de ejemplo, estos anticuerpos y fragmentos de unión al antí­genos de estos pueden comprender polipóptidos de CDR, VH y VL descritos en la presente. En algunas modalidades, estos anticuerpos y fragmentos de unión al antí­geno de estos se unen a y/o compiten por la unión a epí­topos especí­ficos de PACAP humano. La invención está dirigida adicionalmente a utilizar estos anticuerpos anti PACAP antagonistas, y los fragmentos de unión de estos, para el diagnóstico, evaluación, y tratamiento de enfermedades y trastornos asociados con PACAP y afecciones donde el antagonismo de actividades relacionadas con PACAP, tal como vasodilatación, desgranulación de mastocitos y/o activación neuronal son terapóuticamente beneficiosas, por ejemplo en indicaciones para cefalea y migraña.
MX2017013113A 2015-04-16 2016-04-15 Anticuerpos anti-pacap y sus usos. MX2017013113A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562148643P 2015-04-16 2015-04-16
US201562148596P 2015-04-16 2015-04-16
US201562148557P 2015-04-16 2015-04-16
US201562148640P 2015-04-16 2015-04-16
US201562148583P 2015-04-16 2015-04-16
US201562148562P 2015-04-16 2015-04-16
US201562148550P 2015-04-16 2015-04-16
PCT/US2016/027984 WO2016168762A2 (en) 2015-04-16 2016-04-15 Anti-pacap antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2017013113A true MX2017013113A (es) 2018-07-06

Family

ID=57126113

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013113A MX2017013113A (es) 2015-04-16 2016-04-15 Anticuerpos anti-pacap y sus usos.

Country Status (11)

Country Link
US (11) US20160376363A1 (es)
EP (4) EP3283517A4 (es)
JP (6) JP6917899B2 (es)
KR (2) KR20180002685A (es)
CN (2) CN108137677B (es)
AU (3) AU2016249140B8 (es)
CA (4) CA2982861A1 (es)
IL (3) IL254954B (es)
MX (1) MX2017013113A (es)
TW (2) TWI721976B (es)
WO (4) WO2016168760A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017013113A (es) * 2015-04-16 2018-07-06 Alder Biopharmaceuticals Inc Anticuerpos anti-pacap y sus usos.
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
CA3020839A1 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
KR20240052871A (ko) 2016-04-27 2024-04-23 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
US11191752B2 (en) * 2017-04-28 2021-12-07 Case Western Reserve University Compounds and methods of treating retinal degeneration
CN107426040B (zh) * 2017-09-20 2019-08-30 华中科技大学 一种网络行为的预测方法
AR113022A1 (es) * 2017-09-29 2020-01-15 Lilly Co Eli Anticuerpo anti-pacap
WO2019140216A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
US11078283B2 (en) 2018-01-17 2021-08-03 Apexigen, Inc. Anti-PD-L1 antibodies and methods of use
CN109344802B (zh) * 2018-10-29 2021-09-10 重庆邮电大学 一种基于改进的级联卷积神经网的人体疲劳检测方法
GEAP202515689A (en) * 2019-01-08 2025-04-25 H Lundbeck As Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
US20220363770A1 (en) 2019-06-28 2022-11-17 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
JP7370569B2 (ja) * 2019-08-07 2023-10-30 国立大学法人 大分大学 アミロイドβタンパク質オリゴマーと結合するヒト化抗体
CN110632214B (zh) * 2019-10-30 2022-02-25 福州海关技术中心 兽用硫酸庆大霉素中组胺含量的测定方法
BR112022014616A2 (pt) * 2020-01-23 2022-12-13 United Biomedical Inc Imunógenos peptídicos de alvejamento de peptídeo ativador de adenilato ciclase pituitária (pacap) e formulações do mesmo para prevenção e tratamento de enxaqueca
PT4168033T (pt) * 2020-06-21 2026-03-24 Sapience Therapeutics Inc Administração de antagonista de cebp-beta e processos para a sua utilização
IL310329A (en) 2021-07-29 2024-03-01 Cephalon Llc Preparations and methods for anti-PACAP antibodies
JP2023107630A (ja) * 2022-01-24 2023-08-03 国立大学法人横浜国立大学 抗体を製造するための方法及び抗体を評価するための方法並びにこれらに関連するキット
AU2023418913A1 (en) * 2022-12-29 2025-06-19 Biyopharma Co., Ltd Fusion protein
JP2026504452A (ja) * 2023-02-01 2026-02-05 セファロン エルエルシー 抗ＰＡＣＡＰ ＩｇＧ４抗体に関する組成物および方法
WO2024218541A1 (en) * 2023-04-20 2024-10-24 Mark Hasleton Treatment of migraine
CN117503766B (zh) * 2024-01-04 2024-04-26 中国康复研究中心 Pld抑制剂在制备治疗脊髓损伤的药物中的用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1051922A (en) 1908-06-26 1913-02-04 Julius Warren Sheppard Counting mechanism.
US1020243A (en) 1910-06-17 1912-03-12 Gustav Adolf Wlost Resonating device.
US1022837A (en) 1911-03-18 1912-04-09 Charles B French Pneumatic hammer.
US1024773A (en) 1911-04-22 1912-04-30 Forster Mfg Company Machine for stacking toothpicks and the like.
US5198542A (en) 1989-06-20 1993-03-30 Takeda Chemical Industries, Inc. Dna encoding a pitvitary adenylate cyclase activating protein and use thereof
JP3107225B2 (ja) * 1990-03-17 2000-11-06 武田薬品工業株式会社 Ｐａｃａｐに対する抗体およびその用途
EP0618291A3 (en) 1993-02-26 1997-12-03 Takeda Chemical Industries, Ltd. PACAP receptor protein, method for preparing said protein, and use thereof
US6399316B1 (en) 1994-02-25 2002-06-04 Takeda Chemical Industries, Ltd. PACAP receptor protein, method for preparing said protein, and use thereof
JPH11506921A (ja) 1995-06-06 1999-06-22 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒトｇ−タンパク質受容体ｈｃｅｇｈ４５
EP0941327A1 (en) 1996-12-02 1999-09-15 Human Genome Sciences, Inc. Human g-protein receptor hcegh45, a pacap-like (g-protein pituitary adenylate cyclase activating polypeptide-like) receptor
EP1068347A1 (en) 1998-04-03 2001-01-17 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US20020155533A1 (en) 1998-11-30 2002-10-24 Takeda Chemical PACAP receptor protein, method for preparing said protein, and use thereof
AU7726600A (en) 1999-09-28 2001-04-30 Bayer Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
US20020182729A1 (en) 2001-01-11 2002-12-05 Dicicco-Bloom Emanuel Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
US7935500B2 (en) 2002-03-26 2011-05-03 Massachusetts Institute Of Technology Identifying calcineurin activators for treatment of schizophrenia
EP1507551A2 (en) 2002-05-03 2005-02-23 Neuronova AB The functional role and potential therapeutic use of pacap, vip and maxadilan in relation to adult neural stem or progenitor cells
UY27893A1 (es) 2002-07-12 2003-12-31 Bayer Pharmaceuticals Corp Agonistas del receptor (vpac2) del peptido activante de la adenilatociclasa hipofisaria (pacap) y sus metodos de uso farmacologicos
EP1583550A2 (en) * 2003-01-16 2005-10-12 D. Collen Research Foundation vzw Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia
WO2005041757A2 (en) 2003-10-29 2005-05-12 University Of Rochester Detection of neuropeptides associated with pelvic pain disorders and uses thereof
US20050129687A1 (en) 2003-11-03 2005-06-16 University Of Vermont And State Agricultural College Use of inhibitors of PACAP receptor activity for treatment of overactive bladder and pelvic floor pain syndrome
AU2005208911A1 (en) 2004-01-27 2005-08-11 Bayer Healthcare Llc Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonists and their pharmacological methods of use
JPWO2005094881A1 (ja) 2004-03-30 2008-02-14 武田薬品工業株式会社 抗体医薬
EP1814574A4 (en) 2004-10-27 2009-08-05 Univ Denver ANALOGUE OF ADRENOCORTICOTROPEN HORMON AND CORRESPONDING METHODS
WO2006118328A1 (ja) 2005-04-28 2006-11-09 Takeda Pharmaceutical Company Limited 脱顆粒抑制剤
WO2007025286A2 (en) 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
WO2008018472A1 (fr) 2006-08-08 2008-02-14 Kyoto University Nouvel anticorps monoclonal et son utilisation
US7606077B2 (en) 2006-09-12 2009-10-20 Sandisk Corporation Non-volatile memory with reduced erase/write cycling during trimming of initial programming voltage
EP2460828A3 (en) 2006-11-10 2012-08-08 UCB Pharma, S.A. Antibodies and diagnostics
US8466118B2 (en) 2007-04-23 2013-06-18 Saint Louis University Modulation of blood brain barrier protein expression
US20100104530A1 (en) 2007-06-26 2010-04-29 Kathleen Freson Anti-vpac1 antibodies and their uses
EP2009026A1 (en) 2007-06-29 2008-12-31 ThromboGenics N.V. Anti-VPAC1 antibodies and their uses
WO2009033489A2 (en) 2007-09-11 2009-03-19 Glostrup Hospital Selective pacl inhibitors for use in the treatment of migraine and headaches
HRP20241467T1 (hr) 2008-06-25 2025-01-03 Novartis Ag Stabilna i topljiva protutijela koja inhibiraju vegf
CA2730201C (en) * 2008-07-10 2019-02-05 Toray Industries, Inc. Anti-cd179b antibody
CA2730615A1 (en) 2008-07-18 2010-01-21 Galderma Research & Development Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them
JP5172020B2 (ja) * 2008-11-12 2013-03-27 エフ．ホフマン−ラ ロシュ アーゲー 癌のマーカーとしてのｐａｃａｐ
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US8916517B2 (en) * 2009-11-02 2014-12-23 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
JP5728574B2 (ja) 2010-07-21 2015-06-03 アイメックＩｍｅｃ 活性ドーパントプロファイルの決定方法
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
WO2012106407A2 (en) 2011-02-01 2012-08-09 The University Of Vermont And State Agricultural College Diagnostic and therapeutic methods and products related to anxiety disorders
US20120284802A1 (en) 2011-05-02 2012-11-08 Authentec, Inc. Method for playing digital contents protected with a drm (digital right management) scheme and corresponding system
SG10201604040PA (en) 2011-05-20 2016-07-28 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
RS66303B1 (sr) * 2011-05-20 2025-01-31 H Lundbeck As Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
US10052316B2 (en) 2011-06-06 2018-08-21 Cardero Therapeutics, Inc. Methods and compositions for treatment of mitochondrial toxicity
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TWI636064B (zh) * 2013-03-15 2018-09-21 安美基公司 人類ｐａｃ１抗體
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
CN105940014A (zh) 2013-10-25 2016-09-14 努马布有限公司 双特异性构造及其在治疗各种疾病中的用途
US9989541B2 (en) 2013-12-27 2018-06-05 Dignity Health Diagnosing and treating alzheimer's disease
EP3107569A4 (en) 2014-02-20 2018-02-21 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
MX2017013113A (es) * 2015-04-16 2018-07-06 Alder Biopharmaceuticals Inc Anticuerpos anti-pacap y sus usos.
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
CA3020839A1 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
AR113022A1 (es) 2017-09-29 2020-01-15 Lilly Co Eli Anticuerpo anti-pacap

Also Published As

Publication number Publication date
EP3283516A2 (en) 2018-02-21
TWI721975B (zh) 2021-03-21
WO2016168760A1 (en) 2016-10-20
WO2016168762A3 (en) 2016-12-22
WO2016168768A2 (en) 2016-10-20
IL254945A0 (en) 2017-12-31
US12077581B2 (en) 2024-09-03
US20160304604A1 (en) 2016-10-20
JP2023052620A (ja) 2023-04-11
JP2018518659A (ja) 2018-07-12
WO2016168757A1 (en) 2016-10-20
CN108055848B (zh) 2021-10-01
US20160362488A1 (en) 2016-12-15
NZ774247A (en) 2025-02-28
US20220289836A1 (en) 2022-09-15
EP3283169A1 (en) 2018-02-21
US11993648B2 (en) 2024-05-28
JP6752223B2 (ja) 2020-09-09
US10899834B2 (en) 2021-01-26
US20210324068A1 (en) 2021-10-21
JP7219308B2 (ja) 2023-02-07
US20190270807A1 (en) 2019-09-05
US12162936B2 (en) 2024-12-10
EP3283168A4 (en) 2019-03-06
TW201643198A (zh) 2016-12-16
US20210380676A1 (en) 2021-12-09
CA2982861A1 (en) 2016-10-20
US10981985B2 (en) 2021-04-20
WO2016168762A2 (en) 2016-10-20
KR102648281B1 (ko) 2024-03-14
AU2016249406B2 (en) 2021-06-10
NZ736287A (en) 2025-02-28
US10981984B2 (en) 2021-04-20
IL254954B (en) 2021-10-31
CN108137677A (zh) 2018-06-08
AU2016249406A1 (en) 2017-11-09
AU2016249408A1 (en) 2017-11-09
KR20180002685A (ko) 2018-01-08
US20160361441A1 (en) 2016-12-15
US20160376363A1 (en) 2016-12-29
WO2016168768A3 (en) 2016-12-01
US20200172612A1 (en) 2020-06-04
US20210221884A9 (en) 2021-07-22
US20210277106A1 (en) 2021-09-09
EP3283517A4 (en) 2019-03-06
HK1256381A1 (zh) 2019-09-20
JP2021177772A (ja) 2021-11-18
EP3283516A4 (en) 2019-03-06
IL254954A0 (en) 2017-12-31
EP3283168A1 (en) 2018-02-21
CN108055848A (zh) 2018-05-18
EP3283169A4 (en) 2019-03-20
AU2016249140A8 (en) 2022-07-21
CA2983041A1 (en) 2016-10-20
US11254741B2 (en) 2022-02-22
JP2018516071A (ja) 2018-06-21
JP6752222B2 (ja) 2020-09-09
AU2016249140A1 (en) 2017-11-09
TWI721976B (zh) 2021-03-21
KR20180002684A (ko) 2018-01-08
IL254945B (en) 2021-09-30
US20200079847A1 (en) 2020-03-12
CA2982856A1 (en) 2016-10-20
CA2983030A1 (en) 2016-10-20
IL254955B (en) 2021-09-30
JP6924148B2 (ja) 2021-08-25
NZ736285A (en) 2024-11-29
JP2018516361A (ja) 2018-06-21
JP6917899B2 (ja) 2021-08-11
CN108137677B (zh) 2022-01-25
AU2016249140B8 (en) 2022-07-21
AU2016249140B2 (en) 2022-03-24
TW201702266A (zh) 2017-01-16
EP3283517A2 (en) 2018-02-21
IL254955A0 (en) 2017-12-31
JP2018512861A (ja) 2018-05-24
US10844116B2 (en) 2020-11-24

Similar Documents

Publication Publication Date Title
AU2016249140A8 (en) Anti-PACAP antibodies and uses thereof
EP4640706A3 (en) Humanized anti-pacap antibodies and uses thereof
EP4183806A3 (en) Glycan-interacting compounds and methods of use
WO2018026819A3 (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
PH12016502590B1 (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
WO2015157252A8 (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
WO2016090034A3 (en) Methods for b cell preconditioning in car therapy
MX2023000781A (es) Anticuerpos monoclonales anti-cd47 humanizados, de raton, o quimericos.
MY207784A (en) Anti-cd73 antibodies
WO2016187220A3 (en) Anti-ror1 antibodies
CN117417939A8 (zh) 抗TGF-β抗体及其用途
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
HK1250238A1 (zh) 抗angptl8抗体及其用途
HK1254861A1 (zh) 抗lag3抗体及其用途
WO2017087901A3 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
HK1253049A1 (zh) 糖基相互作用化合物及其使用方法
EP3736294A3 (en) Cd73 blockade
WO2016033225A3 (en) Antibodies, compositions, and uses
GEAP202114964A (en) ANTIBODIES TO α-SYNUCLEIN AND USES THEREOF
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
WO2017151971A3 (en) METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
WO2014186599A3 (en) Anti-complement factor c1s antibodies and uses thereof
PH12017501402A1 (en) Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases